Omnicell publishes investor presentation outlining autonomous pharmacy strategy, Titan XT and OmniSphere platform rollout

• Omnicell outlined a strategy centered on autonomous medication management, prioritizing connected automation, innovation-led pharmacy workflows, and expansion across care settings.
• Next-generation Titan XT automated dispensing system, powered by the OmniSphere cloud platform, positioned as the core of an enterprise-wide medication management architecture.
• Recurring revenue emphasis through SaaS and expert services, with recurring revenue projected at 22% of total revenue in 2026.
• Balance sheet described as strong, framed as supporting growth initiatives and a push toward sustainable, profitable growth.
• Product backlog of $640 million and annual recurring revenue of $636 million as of Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omnicell Inc. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.